<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21725">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925612</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-017</org_study_id>
    <nct_id>NCT01925612</nct_id>
  </id_info>
  <brief_title>Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of brentuximab vedotin in
      combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and
      prednisone) (known as A+RCHOP) in patients with DLBCL that have never been treated.
      Patients will be randomly assigned in a 1:1 ratio to receive RCHOP together with 1 of 2
      doses of brentuximab vedotin. Patients will be tested to see if there is a difference in
      side effects between the 2 groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma, B-cell</condition>
  <condition>Lymphoma, Large B-cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles</description>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <other_name>Adcetris; SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles</description>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
    <other_name>Adcetris; SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles</description>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2mg total)</description>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles</description>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles</description>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles</description>
    <arm_group_label>A(1.2 mg/kg)+RCHOP</arm_group_label>
    <arm_group_label>A(1.8 mg/kg)+RCHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naive patients with systemic de novo or transformed diffuse large B cell
             lymphoma (DLBCL) or follicular non-Hodgkin lymphoma (NHL) grade 3b

          -  International Prognostic Index (IPI) score greater than or equal to 3 for patients
             greater than 60 years of age or age-adjusted IPI (aaIPI) score of 2 or 3 for patients
             less than or equal to 60 years of age

          -  Stage IAX (bulk defined as single lymph node mass &gt; 10 cm in diameter), IB-IV disease

          -  Measurable disease of at least 1.5 cm

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

        Exclusion Criteria:

          -  Previous history of treated indolent lymphoma

          -  History of another primary malignancy that has not been in remission for 3 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana Kennedy, PharmD, BCOP</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Lowe</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Mahesh Seetharam, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Department of Hematology and Hematopoietic Cell Transplantation</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Phye</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>89448</phone_ext>
      <email>brbrophy@coh.org</email>
    </contact>
    <investigator>
      <last_name>Lihua Elizabeth Budde, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabata Lund</last_name>
      <phone>650-725-6432</phone>
      <email>sclund@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjana Advani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayo Clinic Clinical Trials ReferralOffice</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Stephen Ansell, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Ley</last_name>
      <phone>314-747-8084</phone>
      <email>ALEY@DOM.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Bartlett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates of Northern New Jersey</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Charles Farber, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Oncology/Hematology Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Merriman</last_name>
      <phone>614-383-6236</phone>
      <email>NMerriman@zangcenter.com</email>
    </contact>
    <investigator>
      <last_name>Mark Knapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hie Sanjorjo</last_name>
      <phone>713-792-4255</phone>
      <email>psanjorjo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Luis Fayad, MD; FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Habte Yimer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112-5550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pena</last_name>
      <phone>801-213-4233</phone>
      <email>karen.pena@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmad Halwani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Dipti Patel-Donnelly, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Scott</last_name>
      <phone>804-628-1909</phone>
      <email>jscott@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Beata Holkova, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Kathryn Kolibaba, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital / North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Jansky</last_name>
      <phone>281-863-6658</phone>
      <email>Melissa.Jansky@Mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boyd, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Lymphoma, B-cell</keyword>
  <keyword>Lymphoma, Large B-cell, Diffuse</keyword>
  <keyword>Monomethyl auristatin E</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
